18889881171
Kalkine 0
countryflagUS
L

AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%
AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%

Denali Therapeutics Inc

Healthcare US DNLI

11.79USD
-1.0(7.82%)

Last update at 2025-04-04T18:52:00Z

Day Range

11.3312.63
LowHigh

52 Week Range

14.5633.31
LowHigh

Fundamentals

  • Previous Close 12.79
  • Market Cap2695.31M
  • Volume967177
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-207.19501M
  • Revenue TTM295.39M
  • Revenue Per Share TTM2.10
  • Gross Profit TTM -250.26900M
  • Diluted EPS TTM-0.94

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-31-300M-250M-200M-150M-100M-50M0M50M100M150M200M250M300M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M200M400M600M800M1000M1200M1400M1600M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-200M-150M-100M-50M0M50M100M150M200M250M300M350M400M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-250M-200M-150M-100M-50M0M50M100M150M200M250M300M350M400M450M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -325.97000M -291.15600M 71.96M -197.96500M -36.24000M
Minority interest - - - - -
Net income -325.99100M -290.58100M 71.14M -197.61400M -36.24000M
Selling general administrative 90.47M 79.06M 60.33M 46.48M 32.35M
Selling and marketing expenses - - - - -
Gross profit 108.46M 48.66M 335.66M 26.68M 129.16M
Reconciled depreciation 10.38M 8.59M 8.53M 7.99M 7.42M
Ebit -340.74400M -304.34400M 54.19M -221.17500M -53.78700M
Ebitda -330.36100M -295.75100M 62.72M -213.18400M -46.37200M
Depreciation and amortization 10.38M 8.59M 8.53M 7.99M 7.42M
Non operating income net other - 4.59M 9.24M 15.22M 10.13M
Operating income -340.74400M -295.75100M 62.72M -213.18400M -46.37200M
Other operating expenses 449.21M 344.41M 272.94M 239.86M 175.53M
Interest expense 14.77M 13.19M 17.77M 15.22M 0.00000M
Tax provision 0.02M -0.57500M 0.82M -0.35100M -
Interest income 14.77M 4.59M - 15.22M 10.13M
Net interest income 14.77M 4.59M 9.24M 15.22M 10.13M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M -0.57500M 0.82M -0.35100M 10.13M
Total revenue 108.46M 48.66M 335.66M 26.68M 129.16M
Total operating expenses 449.21M 344.41M 272.94M 239.86M 175.53M
Cost of revenue - - - 193.38M 143.18M
Total other income expense net 14.77M 4.59M 9.24M 15.22M 10.13M
Discontinued operations - - - - -
Net income from continuing ops -325.99100M -290.58100M 72.78M -197.61400M -36.24000M
Net income applicable to common shares -325.99100M -290.58100M 71.14M -197.61400M -36.24000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1153.92M 1460.24M 1404.16M 1604.28M 553.23M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 26.93M 36.10M 30.60M 20.28M 14.68M
Total liab 122.96M 417.81M 441.87M 453.75M 158.34M
Total stockholder equity 1030.95M 1042.43M 962.29M 1150.53M 394.89M
Deferred long term liab - - - - -
Other current liab 61.24M 63.76M 47.71M 42.45M 20.35M
Common stock 1.71M 1.69M 1.55M 1.53M 1.29M
Capital stock 1.71M 1.69M 1.55M 1.53M 1.29M
Retained earnings -1116.21100M -970.98700M -644.99600M -354.41500M -425.55100M
Other liab - 0.86M 5.07M 317.88M 44.13M
Good will - - - - -
Other assets 0.00000M 13.40M 11.87M 2.46M 2.66M
Cash 127.11M 218.04M 293.48M 507.14M 79.45M
Cash and equivalents - - - - -
Total current liabilities 77.98M 363.92M 378.25M 71.70M 45.34M
Current deferred revenue - 290.05M 320.30M 23.48M 18.74M
Net debt -74.86500M -157.69400M -234.92300M -442.96900M -10.58400M
Short term debt 7.26M 7.32M 5.45M 4.69M 3.67M
Short long term debt - - - - -
Short long term debt total 52.24M 60.35M 58.55M 64.17M 68.86M
Other stockholder equity 2144.81M 2018.62M 1608.24M 1503.66M 818.80M
Property plant equipment - 74.52M 69.61M 40.85M 80.66M
Total current assets 1064.14M 1372.32M 897.23M 1495.65M 430.03M
Long term investments - 0.00000M 425.45M 32.70M 39.89M
Net tangible assets - 1042.43M 962.29M 1150.53M 394.89M
Short term investments 907.40M 1118.17M 571.93M 962.55M 335.91M
Net receivables 2.70M - 1.23M 5.67M -
Long term debt - - - - -
Inventory 0.00000M - - - -
Accounts payable 9.48M 2.79M 4.78M 1.07M 2.59M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.64M -6.88600M -2.49900M -0.24500M 0.35M
Additional paid in capital - - - - -
Common stock total equity - - 1.55M 1.53M 1.29M
Preferred stock total equity - - - - -
Retained earnings total equity - - -644.99600M -354.41500M -425.55100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 16.54M 13.40M 11.87M 2.46M 2.66M
Deferred long term asset charges - - - - -
Non current assets total 89.78M 87.92M 506.93M 108.62M 123.20M
Capital lease obligations 52.24M 60.35M 58.55M 68.86M 72.53M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -141.38700M -13.12600M -620.11100M 165.63M -284.02900M
Change to liabilities -32.18800M -11.95700M 20.80M 2.53M 8.97M
Total cashflows from investing activities -141.38700M -21.62600M -623.20600M 147.71M -287.42200M
Net borrowings - - - - -
Total cash from financing activities 310.67M 19.35M 634.75M 6.19M 97.02M
Change to operating activities 8.16M -8.45500M 11.86M 9.43M -5.36000M
Net income -325.99100M -290.58100M 71.14M -197.61400M -36.24000M
Change in cash -75.43300M -213.66700M 427.69M 2.33M -140.28700M
Begin period cash flow 294.98M 508.64M 80.95M 78.62M 218.91M
End period cash flow 219.54M 294.98M 508.64M 80.95M 78.62M
Total cash from operating activities -244.71600M -211.38900M 416.15M -151.57600M 50.12M
Issuance of capital stock 296.21M 0.00000M 614.09M 0.00000M 94.41M
Depreciation 10.38M 8.59M 8.53M 7.99M 7.42M
Other cashflows from investing activities - - - 165.63M -284.02900M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 19.35M 214.60M 6.19M 2.61M
Other cashflows from financing activities 14.46M 19.35M 20.66M 6.19M 2.61M
Change to netincome 94.92M 91.01M 50.39M 38.03M 18.75M
Capital expenditures 17.83M 8.50M 3.10M 17.92M 3.39M
Change receivables - - - - -
Cash flows other operating - -31.51100M 265.24M 2.51M 53.92M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -213.66700M 427.69M 2.33M -140.28700M
Change in working capital -24.03000M -20.41200M 288.40M 4.17M 62.89M
Stock based compensation 99.85M 85.25M 50.35M 38.38M 18.79M
Other non cash items -4.92500M -2.98400M -2.32200M 0.51M -2.74100M
Free cash flow -262.54900M -219.88900M 413.06M -169.49500M 46.72M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DNLI
Denali Therapeutics Inc		 -1.0 7.82% 11.79 - - 7.69 2.46 4.72 -8.6613
NVO
Novo Nordisk A/S		 -4.44 6.62% 62.66 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.842 5.72% 63.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -5.74 1.19% 478.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -27.19 4.45% 583.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc

161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Ryan J. Watts Ph.D. Co-Founder, Pres, CEO & Director 1976
Dr. Alexander O. Schuth M.D. Co-Founder, CFO, COO & Sec. 1973
Dr. Marc Tessier-Lavigne Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director 1960
Dr. Carole Ho M.D. Chief Medical Officer & Head of Devel. 1973
Mr. Steve Edward Krognes Treasurer & Director 1968
Mr. Tyler M. Nielsen Sr. VP of Corp. Fin. 1978
Dr. Dana Andersen Chief Technical and Manufacturing Officer NA
Mr. Joe Lewcock Chief Scientific Officer NA
Dr. Laura Hansen VP of Investor Relations NA
Mr. Chris Walsh Gen. Counsel NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.